about
Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disordersWhat can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?α-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter.A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonismCommentary: Evaluation of Models of Parkinson's DiseaseThe Chemistry of Neurodegeneration: Kinetic Data and Their Implications.Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer.Trait Impulsivity and Anhedonia: Two Gateways for the Development of Impulse Control Disorders in Parkinson's Disease?Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity.Molecular imaging of levodopa-induced dyskinesias.The role of neurotransmitters in the development of Parkinson's disease-related psychosis.Effects of Physical Rehabilitation Integrated with Rhythmic Auditory Stimulation on Spatio-Temporal and Kinematic Parameters of Gait in Parkinson's Disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies.Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.Pannexin hemichannels: A novel promising therapy target for oxidative stress related diseases.Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal follow-up study.Qigong Exercise May Reduce Serum TNF-α Levels and Improve Sleep in People with Parkinson's Disease: A Pilot Study.Restless legs syndrome in Parkinson disease: Clinical characteristics, abnormal iron metabolism and altered neurotransmitters.PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease.Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis.Network and Pathway-Based Analyses of Genes Associated with Parkinson's Disease.The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies.Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.Serotonergic loss underlying apathy in Parkinson's disease.The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar Outcomes.Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson's Disease.5-HT1a Receptor Involvement in Temporal Memory and the Response to Temporal Ambiguity.Biochemical and Functional Changes in the Eye As a Manifestation of Systemic Degeneration of the Nervous System in Parkinsonism
P2860
Q21146612-BA923973-528A-4B2D-9A24-173732E08367Q26767268-47D90A11-4157-44ED-9A36-D637D9F63EAEQ27313863-4B307BAA-76C1-44E4-9DB4-20D816882ABDQ28075227-CE49B1AA-FB75-4054-9232-7E8FCA2F33B5Q28397369-293FCDB1-EA28-46CA-9A70-7163261E12C9Q30973484-0F7E727C-B847-4472-B6C4-DAEE61A2B5C0Q36789528-A244AC56-9CB9-467A-A404-CA95A4A0D7A6Q36946063-1BB60313-2514-491F-B3E3-C43D7213ABDBQ37325666-E50136AD-56C9-4A53-A282-3E8499F431ABQ38355582-420A0F80-1FA4-4836-AB5F-321FA5E657BBQ38649501-25FD5525-99F5-4E22-BD27-973762A86B77Q38827653-3C900E4B-8F5A-4D97-9FC0-47B45A48210BQ38845546-925E0734-E3A9-4B19-8C63-6ABF448CE280Q39055550-849987E3-6B39-436D-BD28-CEF767137AB8Q39125374-AFF9CD33-CB34-41C7-A2B6-CBA1DC6D823FQ39179457-90BAAB1D-2F31-4147-B184-258023397598Q40790760-98715185-9DEF-4FC7-913A-F17E10F8A13AQ40924267-623BC279-DBE7-4F96-A13C-573946921EE7Q41529537-AAF890FD-3F61-4B0F-8A43-A8300B1B9516Q41620070-61707830-B287-4780-9842-85FFBE3BBBFBQ42369736-F15D3BEB-6DAC-45F5-BF40-75539E389BE7Q47146437-12FF8CDF-6F2B-4698-A123-A1C174BE43F0Q47319471-22D15FBD-41F9-4A7D-8D4C-A7DD88A63313Q48184416-8DDD6B1F-2840-4F3C-A423-79731583BCF7Q48372783-E7A94A73-15AF-4FE3-98CA-46018F610001Q48492369-34E2CEBB-C5E7-4700-A7EB-1C69343488FAQ48553538-71C1C1D9-0090-4371-954C-7324FF67CA95Q50876872-6A1411AF-5B06-4C21-B863-69C72C1986A2Q51583546-2E812434-3EDE-4ABD-B51E-2E683ACEC41EQ52332824-A27EBB18-0612-4EE0-9FB1-4455C90278B6Q54013959-B45CAA76-7E0B-4986-8C48-ED94BCF843C9Q55717818-6990769A-1624-4FF6-ABEE-B8CE0CE0884DQ58568981-8ED75E91-27F1-4734-98BF-1740A72A896C
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Serotonin in Parkinson's disease.
@en
type
label
Serotonin in Parkinson's disease.
@en
prefLabel
Serotonin in Parkinson's disease.
@en
P1476
Serotonin in Parkinson's disease.
@en
P2093
Flavia Niccolini
Marios Politis
P304
P356
10.1016/J.BBR.2014.07.037
P407
P577
2014-07-31T00:00:00Z